News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cognoptix Drug/Device Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in a 10-Subject Proof-of-Concept Clinical Trial


1/3/2013 9:36:40 AM

ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company announced today that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial. By detecting a specific fluorescent signature of ligand-marked beta-amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a two-fold differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer’s disease.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES